Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis
Abstract Background The oral acceptance of oclacitinib maleate (Apoquel®) chewable tablets administered twice daily for 7 days at the labeled dose range of 0.4–0.6 mg/kg was evaluated in 121 dogs treated at ten general practice veterinary clinics in the United States. Results Dogs that were enrolled...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-03-01
|
| Series: | BMC Veterinary Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12917-022-03210-x |
| _version_ | 1818320984414879744 |
|---|---|
| author | Marike Visser Kelly Walsh Vickie King Gordon Sture Laura Caneva |
| author_facet | Marike Visser Kelly Walsh Vickie King Gordon Sture Laura Caneva |
| author_sort | Marike Visser |
| collection | DOAJ |
| description | Abstract Background The oral acceptance of oclacitinib maleate (Apoquel®) chewable tablets administered twice daily for 7 days at the labeled dose range of 0.4–0.6 mg/kg was evaluated in 121 dogs treated at ten general practice veterinary clinics in the United States. Results Dogs that were enrolled in the study were client-owned, ranged from 1 to 14 years of age, weighed 3.7 to 60.7 kg, and required twice daily treatment with Apoquel for allergic or atopic dermatitis for 7 days. One hundred and twenty-one (121) dogs with 1673 total dose administrations successfully completed the study and were included in the data summary. Out of a total number of 1673 administrations, 1533 (91.6%) were accepted voluntarily within 5 min, 134 (8%) were consumed with assistance (with food treats or by pilling) outside of the 5 min offering time and 6 (0.4%) doses were not consumed. The per dose percent acceptance rate for the 14 offered doses showed minimal variation ranging from 89.9 to 93.3%. Conclusions Client-owned dogs from the general veterinary patient population that required treatment with oclacitinib found the chewable tablets to be very palatable and no aversion occurred with repeated dosing. Oclacitinib chewable tablets were well tolerated and are a palatable alternative to the film-coated tablet. |
| first_indexed | 2024-12-13T10:33:41Z |
| format | Article |
| id | doaj.art-686d5b3a88bf4de186c0efefcac0d062 |
| institution | Directory Open Access Journal |
| issn | 1746-6148 |
| language | English |
| last_indexed | 2024-12-13T10:33:41Z |
| publishDate | 2022-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Veterinary Research |
| spelling | doaj.art-686d5b3a88bf4de186c0efefcac0d0622022-12-21T23:50:47ZengBMCBMC Veterinary Research1746-61482022-03-011811510.1186/s12917-022-03210-xAcceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitisMarike Visser0Kelly Walsh1Vickie King2Gordon Sture3Laura Caneva4Zoetis VMRDZoetis VMRDZoetis VMRDZoetis VMRDZoetis Belgium SAAbstract Background The oral acceptance of oclacitinib maleate (Apoquel®) chewable tablets administered twice daily for 7 days at the labeled dose range of 0.4–0.6 mg/kg was evaluated in 121 dogs treated at ten general practice veterinary clinics in the United States. Results Dogs that were enrolled in the study were client-owned, ranged from 1 to 14 years of age, weighed 3.7 to 60.7 kg, and required twice daily treatment with Apoquel for allergic or atopic dermatitis for 7 days. One hundred and twenty-one (121) dogs with 1673 total dose administrations successfully completed the study and were included in the data summary. Out of a total number of 1673 administrations, 1533 (91.6%) were accepted voluntarily within 5 min, 134 (8%) were consumed with assistance (with food treats or by pilling) outside of the 5 min offering time and 6 (0.4%) doses were not consumed. The per dose percent acceptance rate for the 14 offered doses showed minimal variation ranging from 89.9 to 93.3%. Conclusions Client-owned dogs from the general veterinary patient population that required treatment with oclacitinib found the chewable tablets to be very palatable and no aversion occurred with repeated dosing. Oclacitinib chewable tablets were well tolerated and are a palatable alternative to the film-coated tablet.https://doi.org/10.1186/s12917-022-03210-xApoquelAllergic dermatitisAtopic dermatitisChewableOclacitinib maleateDog |
| spellingShingle | Marike Visser Kelly Walsh Vickie King Gordon Sture Laura Caneva Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis BMC Veterinary Research Apoquel Allergic dermatitis Atopic dermatitis Chewable Oclacitinib maleate Dog |
| title | Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis |
| title_full | Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis |
| title_fullStr | Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis |
| title_full_unstemmed | Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis |
| title_short | Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis |
| title_sort | acceptance of oclacitinib maleate apoquel r chewable tablets in client owned dogs with allergic and atopic dermatitis |
| topic | Apoquel Allergic dermatitis Atopic dermatitis Chewable Oclacitinib maleate Dog |
| url | https://doi.org/10.1186/s12917-022-03210-x |
| work_keys_str_mv | AT marikevisser acceptanceofoclacitinibmaleateapoquelchewabletabletsinclientowneddogswithallergicandatopicdermatitis AT kellywalsh acceptanceofoclacitinibmaleateapoquelchewabletabletsinclientowneddogswithallergicandatopicdermatitis AT vickieking acceptanceofoclacitinibmaleateapoquelchewabletabletsinclientowneddogswithallergicandatopicdermatitis AT gordonsture acceptanceofoclacitinibmaleateapoquelchewabletabletsinclientowneddogswithallergicandatopicdermatitis AT lauracaneva acceptanceofoclacitinibmaleateapoquelchewabletabletsinclientowneddogswithallergicandatopicdermatitis |